Cited by 1,088Cystic Fibrosis Research AdvancesIon Transport and Channel RegulationInhalation and Respiratory Drug Delivery

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Open access

Van Goor, Fredrick, Hadida, Sabine, Grootenhuis, Peter D. J., Burton, Bill, Stack, Jeffrey H., Straley, Kimberly S., Decker, Caroline J., Miller, Mark, McCartney, Jason, Olson, Eric R., Wine, Jeffrey J., Frizzell, Ray A., Ashlock, Melissa, Negulescu, Paul A.·2011·Proceedings of the National Academy of Sciences

DOI 10.1073/pnas.1105787108PMC PMC3219147

Open this paper in CoChat — free account

Abstract

Cystic fibrosis (CF) is caused by mutations in the CF transmembrane conductance regulator ( CFTR ) gene that impair the function of CFTR, an epithelial chloride channel required for proper function of the lung, pancreas, and other organs. Most patients with CF carry the F508del CFTR mutation, which causes defective CFTR protein folding and processing in the endoplasmic reticulum, resulting in minimal amounts of CFTR at the cell surface. One strategy to treat these patients is to correct the processing of F508del-CFTR with small molecules. Here we describe the in vitro pharmacology of VX-809, a CFTR corrector that was advanced into clinical development for the treatment of CF. In cultured human bronchial epithelial cells isolated from patients with CF homozygous for F508del, VX-809 improved F508del-CFTR processing in the endoplasmic reticulum and enhanced chloride secretion to approximately 14% of non-CF human bronchial epithelial cells (EC 50 , 81 ± 19 nM), a level associated with mild CF in patients with less disruptive CFTR mutations. F508del-CFTR corrected by VX-809 exhibited biochemical and functional characteristics similar to normal CFTR, including biochemical susceptibility to proteolysis, residence time in the plasma membrane, and single-channel open probability. VX-809 was more efficacious and selective for CFTR than previously reported CFTR correctors. VX-809 represents a class of CFTR corrector that specifically addresses the underlying processing defect in F508del-CFTR.

Integrity signals

Registry

Crossref · 10.1073/pnas.1105787108

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA
Riordan, J. R., Rommens, J. M., Kerem, B.-S., Alon, N., Rozmahel, R., Grzelczak, Z., Zielenski, J., Lok, S., Plavsic, N., Chou, J.-L., et al. (1989) · Science · doi:10.1126/science.2475911 · Cited by 7,418
Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis
Cheng, S. H., Gregory, R. J., Marshall, J., Paul, S., Souza, D. W., White, G. A., O’Riordan, C. R., & Smith, A. E. (1990) · Cell · doi:10.1016/0092-8674(90)90148-8 · Cited by 1,792
Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive
Denning, G. M., Anderson, M. P., Amara, J. F., Marshall, J., Smith, A. E., & Welsh, M. J. (1992) · Nature · doi:10.1038/358761a0 · Cited by 1,236
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Goor, F. V., Hadidaꝉ, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A. K., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,225
Self-citation
Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report
Farrell, P. M., Rosenstein, B. J., White, T. B., Accurso, F. J., Castellani, C., Cutting, G. R., Durie, P. R., LeGrys, V. A., Massie, J., Parad, R. B., et al. (2008) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2008.05.005 · Cited by 1,093
Cystic fibrosis: A worldwide analysis ofCFTR mutations?correlation with incidence data and application to screening
Bobadilla, J. L., Macek, M., Fine, J. P., & Farrell, P. M. (2002) · Human Mutation · doi:10.1002/humu.10041 · Cited by 1,032
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- CFTR Mutation
Accurso, F. J., Rowe, S. M., Clancy, J. P., Boyle, M., Dunitz, J., Durie, P. R., Sagel, S. D., Hornick, D. B., Konstan, M. W., Donaldson, S. H., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909825 · Cited by 803
Self-citation
Altered chloride ion channel kinetics associated with the ΔF508 cystic fibrosis mutation
Dalemans, W., Barbry, P., Champigny, G., Jallat, S., Jallat, S., Dott, K., Dreyer, D., Crystal, R. G., Pavirani, A., Lecocq, J.-P., et al. (1991) · Nature · doi:10.1038/354526a0 · Cited by 707
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice
Castellani, C., Cuppens, H., Maçek, M., Cassiman, J. J., Kerem, E., Durie, P. R., Tullis, E. D., Assael, B. M., Bombieri, C., Brown, A., et al. (2008) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.03.009 · Cited by 624
Small-molecule correctors of defective F508-CFTR cellular processing identified by high-throughput screening
Pedemonte, N. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24898 · Cited by 551

Show all 44 references

Research works printed but not linked: 1

; Cystic Fibrosis Foundation US Cystic Fibrosis Patient Registry (Cystic Fibrosis Foundation, Bethesda, 2002).

Sorted by citations

Items 401–500 of 1,000

Proteomic interaction profiling reveals KIFC1 as a factor involved in early targeting of F508del-CFTR to degradation
Canato, S., Santos, J. D., Carvalho, A. S., Aloria, K., Amaral, M. D., Matthiesen, R., Falcão, A. O., & Farinha, C. M. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2896-7 · Cited by 34
Evaluation of 1,2,3‐Triazoles as Amide Bioisosteres In Cystic Fibrosis Transmembrane Conductance Regulator Modulators VX‐770 and VX‐809
Doiron, J. E., Le, C. A., Ody, B. K., Brace, J. B., Post, S. J., Thacker, N. L., Hill, H. M., Breton, G. W., Mulder, M. J., Chang, S., et al. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201805919 · Cited by 33
Cystic fibrosis precision therapeutics: Emerging considerations
Joshi, D., Ehrhardt, A., Hong, J. S., & Sorscher, E. J. (2019) · Pediatric Pulmonology · doi:10.1002/ppul.24547 · Cited by 33
Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222
Singh, A. K., Fan, Y., Balut, C., Alani, S., Manelli, A. M., Swensen, A. M., Jia, Y., Neelands, T. R., Vortherms, T. A., Liu, B., et al. (2019) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.261800 · Cited by 32
Synthesis and Therapeutic Applications of Iminosugars in Cystic Fibrosis
Esposito, A., D’Alonzo, D., Fenza, M. D., Gregorio, E. D., Tamanini, A., Lippi, G., Dechecchi, M. C., & Guaragna, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093353 · Cited by 33
Folliculin variants linked to Birt-Hogg-Dubé syndrome are targeted for proteasomal degradation
Clausen, L., Stein, A., Grønbæk-Thygesen, M., Nygaard, L., Søltoft, C. L., Nielsen, S. V., Lisby, M., Ravid, T., Lindorff‐Larsen, K., & Hartmann‐Petersen, R. (2020) · PLoS Genetics · doi:10.1371/journal.pgen.1009187 · Cited by 33
Differential thermostability and response to cystic fibrosis transmembrane conductance regulator potentiators of human and mouse F508del-CFTR
Bose, S. J., Bijvelds, M. J. C., Wang, Y., Liu, J., Cai, Z., Bot, A. G. M., de Jonge, H. R., & Sheppard, D. N. (2019) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00034.2019 · Cited by 33
Emerging drugs for cystic fibrosis
Amin, R., & Ratjen, F. A. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.882316 · Cited by 32
ΔF508 CFTR Surface Stability Is Regulated by DAB2 and CHIP-Mediated Ubiquitination in Post-Endocytic Compartments
Fu, L., Rab, A., Tang, L. P., Bebők, Z., Rowe, S. M., Bartoszewski, R., & Collawn, J. F. (2015) · PLoS ONE · doi:10.1371/journal.pone.0123131 · Cited by 33
Human induced pluripotent stem cells for monogenic disease modelling and therapy
Spitalieri, P., Talarico, V. R., Murdocca, M., Novelli, G., & Sangiuolo, F. C. (2016) · World Journal of Stem Cells · doi:10.4252/wjsc.v8.i4.118 · Cited by 34
Recent Progress in the Discovery and Development of Small-Molecule Modulators of CFTR
Kym, P. R., Wang, X., Pizzonero, M., & der Plas, S. E. V. (2018) · Progress in medicinal chemistry · doi:10.1016/bs.pmch.2018.01.001 · Cited by 34
Correcting the F508del-CFTR variant by modulating eukaryotic translation initiation factor 3–mediated translation initiation
Hutt, D. M., Loguercio, S., Roth, D., Su, A. I., & Balch, W. E. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003192 · Cited by 33
Structural dynamics of membrane-protein folding from single-molecule FRET
Krainer, G., Keller, S., & Schlierf, M. (2019) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2019.05.025 · Cited by 32
Small Molecule Anion Carriers Correct Abnormal Airway Surface Liquid Properties in Cystic Fibrosis Airway Epithelia
Gianotti, A., Capurro, V., Delpiano, L., Mielczarek, M., García‐Valverde, M., Carreira‐Barral, I., Ludovico, A., Fiore, M., Baroni, D., Morán, Ó., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041488 · Cited by 32
Open reading frame correction using splice-switching antisense oligonucleotides for the treatment of cystic fibrosis
Michaels, W. E., Peña‐Rasgado, C., Kotaria, R., Bridges, R. J., & Hastings, M. L. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114886119 · Cited by 31
Capturing the Direct Binding of CFTR Correctors to CFTR by Using Click Chemistry
Sinha, C., Zhang, W., Moon, C., Actis, M. L., Yarlagadda, S., Arora, K., Woodrooffe, K., Clancy, J. P., Lin, S., Ziady, A. G., et al. (2015) · ChemBioChem · doi:10.1002/cbic.201500123 · Cited by 32
Self-citation
Activation of 3-Phosphoinositide-dependent Kinase 1 (PDK1) and Serum- and Glucocorticoid-induced Protein Kinase 1 (SGK1) by Short-chain Sphingolipid C4-ceramide Rescues the Trafficking Defect of ΔF508-Cystic Fibrosis Transmembrane Conductance Regulator (ΔF508-CFTR)
Caohuy, H., Yang, Q., Eudy, Y., Ha, T.-A., Xu, A. E., Glover, M. L., Frizzell, R. A., Jozwik, C., & Pollard, H. B. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.598649 · Cited by 31
Self-citation
Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor
Rubin, J. L., O’Callaghan, L., Pelligra, C. G., Konstan, M. W., Ward, A. J., Ishak, J. K., Chandler, C., & Liou, T. G. (2019) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618820186 · Cited by 33
SYVN1, NEDD8, and FBXO2 Proteins Regulate ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Ubiquitin-mediated Proteasomal Degradation
Ramachandran, S. S., Osterhaus, S. R., Parekh, K. R., Jacobi, A. M., Behlke, M. A., & McCray, P. B. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.754283 · Cited by 32
A Comparison between Two Pathophysiologically Different yet Microbiologically Similar Lung Diseases: Cystic Fibrosis and Chronic Obstructive Pulmonary Disease
Fenker, D. E., McDaniel, C. T., Panmanee, W., Panos, R. J., Sorscher, E. J., Sabusap, C. M. P., Clancy, J. P., & Hassett, D. J. (2018) · International Journal of Respiratory and Pulmonary Medicine · doi:10.23937/2378-3516/1410098 · Cited by 32
Towards next generation therapies for cystic fibrosis: Folding, function and pharmacology of CFTR
Bose, S. J., Krainer, G., Ng, D. R. S., Schenkel, M., Shishido, H., Yoon, J. S., Haggie, P. M., Schlierf, M., Sheppard, D. N., & Skach, W. R. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2019.12.009 · Cited by 33
Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events
Schwarz, C., Sutharsan, S., Epaud, R., Klingsberg, R. C., Fischer, R., Rowe, S. M., Audhya, P., Ahluwalia, N., You, X., Ferro, T. J., et al. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.06.001 · Cited by 32
Pathophysiology of Lung Disease and Wound Repair in Cystic Fibrosis
Conese, M., & Gioia, S. D. (2021) · Pathophysiology · doi:10.3390/pathophysiology28010011 · Cited by 32
State of the Art on Approved Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators and Triple-Combination Therapy
Meoli, A., Fainardi, V., Deolmi, M., Chiopris, G., Marinelli, F., Caminiti, C., Esposito, S., & Pisi, G. (2021) · Pharmaceuticals · doi:10.3390/ph14090928 · Cited by 36
One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies
Ensinck, M. M., & Carlon, M. S. (2022) · Cells · doi:10.3390/cells11121868 · Cited by 33
Discovery of Multitarget Agents Active as Broad-Spectrum Antivirals and Correctors of Cystic Fibrosis Transmembrane Conductance Regulator for Associated Pulmonary Diseases
Tassini, S., Sun, L., Lanko, K., Crespan, E., Langron, E., Falchi, F., Kiššová, M., Rivera, J. I. A., Delang, L., Mirabelli, C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01521 · Cited by 31
General trends in the effects of VX-661 and VX-445 on the plasma membrane expression of clinical CFTR variants
McKee, A. G., McDonald, E. F., Penn, W. D., Kuntz, C. P., Noguera, K., Chamness, L. M., Roushar, F. J., Meiler, J., Oliver, K. E., Plate, L., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.05.001 · Cited by 30
Spondylocheirodysplastic Ehlers-Danlos syndrome (SCD-EDS) and the mutant zinc transporter ZIP13
Bin, B.-H., Hojyo, S., Lee, T. R., & Fukada, T. (2014) · Rare Diseases · doi:10.4161/21675511.2014.974982 · Cited by 30
Nasal Epithelial Cell-Based Models for Individualized Study in Cystic Fibrosis
Keegan, D., & Brewington, J. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094448 · Cited by 29
CFTR pharmacology
Zegarra‐Moran, O., & Galietta, L. J. V. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2392-x · Cited by 33
Rescue of defective ATP8B1 trafficking by CFTR correctors as a therapeutic strategy for familial intrahepatic cholestasis
van der Woerd, W. L., Wichers, C. G. K., Vestergaard, A. L., Andersen, J. P., Paulusma, C. C., Houwen, R. H. J., & van de Graaf, S. F. J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.001 · Cited by 30
Is cellular senescence involved in cystic fibrosis?
Bezzerri, V., Piacenza, F., Caporelli, N., Malavolta, M., Provinciali, M., & Cipolli, M. (2019) · Respiratory Research · doi:10.1186/s12931-019-0993-2 · Cited by 31
Advancing Treatment Strategies: A Comprehensive Review of Drug Delivery Innovations for Chronic Inflammatory Respiratory Diseases
Wang, J., Wang, P., Shao, Y., & He, D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082151 · Cited by 30
Elexacaftor/VX-445–mediated CFTR interactome remodeling reveals differential correction driven by mutation-specific translational dynamics
Kim, M., McDonald, E. F., Sabusap, C. M. P., Timalsina, B., Joshi, D., Hong, J. S., Rab, A., Sorscher, E. J., & Plate, L. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105242 · Cited by 28
Epithelial Sodium Channel Silencing as a Strategy to Correct the Airway Surface Fluid Deficit in Cystic Fibrosis
Gianotti, A., Melani, R., Caci, E., Sondo, E., Ravazzolo, R., Galietta, L. J. V., & Zegarra‐Moran, O. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0408oc · Cited by 29
Nonsense Suppression as an Approach to Treat Lysosomal Storage Diseases
Keeling, K. M. (2016) · Diseases · doi:10.3390/diseases4040032 · Cited by 30
Corrector combination therapies for F508del-CFTR
Hanrahan, J. W., Matthes, E., Carlile, G. W., & Thomas, D. Y. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.09.016 · Cited by 29
Hsp70 and DNAJA2 limit CFTR levels through degradation
Chiaw, P. K., Hantouche, C., Wong, M. J. H., Matthes, E., Robert, R., Hanrahan, J. W., Shrier, A., & Young, J. C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220984 · Cited by 29
An Intriguing Involvement of Mitochondria in Cystic Fibrosis
Favia, M., Lidia de, B. A. R. I., Bobba, A., & Atlante, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111890 · Cited by 30
Current development of CFTR potentiators in the last decade
Spanò, V., Venturini, A., Genovese, M., Barreca, M., Raimondi, M. V., Montalbano, A., Galietta, L. J. V., & Barraja, P. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112631 · Cited by 30
An update on new and emerging therapies for cystic fibrosis
Hudock, K. M., & Clancy, J. P. (2017) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2017.1418324 · Cited by 28
HDAC inhibitors rescue multiple disease-causing CFTR variants
Anglès, F., Hutt, D. M., & Balch, W. E. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz026 · Cited by 28
Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein
Spanò, V., Barreca, M., Cilibrasi, V., Genovese, M., Renda, M., Montalbano, A., Galietta, L. J. V., & Barraja, P. (2021) · Molecules · doi:10.3390/molecules26051275 · Cited by 28
Targeted therapy for cystic fibrosis
Kutsev, S. I., Izhevskaya, V. L., & Kondratyeva, E. (2021) · PULMONOLOGIYA · doi:10.18093/0869-0189-2021-31-2-226-236 · Cited by 31
Chloride transport modulators as drug candidates
Verkman, A. S., & Galietta, L. J. V. (2021) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00334.2021 · Cited by 28
SERCA and PMCA pumps contribute to the deregulation of Ca2+ homeostasis in human CF epithelial cells
Philippe, R., Antigny, F., Buscaglia, P., Norez, C., Becq, F., Frieden, M., & Mignen, O. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.01.010 · Cited by 28
Curcumin and Genistein: the Combined Effects on Disease-associated CFTR Mutants and their Clinical Implications
Sohma, Y., Yu, Y.-C., & Hwang, T.-C. (2013) · Current Pharmaceutical Design · doi:10.2174/13816128113199990320 · Cited by 27
Lumacaftor/ivacaftor combination for cystic fibrosis patients homozygous for Phe508del-CFTR
Zhang, W., Zhang, X., Zhang, Y. H., Stokes, D. C., & Naren, A. P. (2016) · Drugs of today · doi:10.1358/dot.2016.52.4.2467205 · Cited by 26
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics
Chung, W. J., Goeckeler-Fried, J. L., Havasi, V., Chiang, A., Rowe, S. M., Plyler, Z. E., Hong, J. S., Mazur, M., Piazza, G. A., Keeton, A. B., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163615 · Cited by 28
Quorum Sensing Down-Regulation Counteracts the Negative Impact of Pseudomonas aeruginosa on CFTR Channel Expression, Function and Rescue in Human Airway Epithelial Cells
Maillé, É., Ruffin, M., Adam, D., Messaoud, H., LaFayette, S. L., McKay, G. A., Nguyen, D. M., & Brochiero, E. (2017) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2017.00470 · Cited by 29
Prolonged co-treatment with HGF sustains epithelial integrity and improves pharmacological rescue of Phe508del-CFTR
Matos, A. M., Gomes‐Duarte, A., Faria, M., Barros, P., Jordan, P., Amaral, M. D., & Matos, P. (2018) · Scientific Reports · doi:10.1038/s41598-018-31514-2 · Cited by 29
A minimal helical-hairpin motif provides molecular-level insights into misfolding and pharmacological rescue of CFTR
Krainer, G., Treff, A., Hartmann, A. J., Stone, T. A., Schenkel, M., Keller, S., Deber, C. M., & Schlierf, M. (2018) · Communications Biology · doi:10.1038/s42003-018-0153-0 · Cited by 28
Local modulation of cystic fibrosis conductance regulator: cytoskeleton and compartmentalized cAMP signalling
Monterisi, S., Casavola, V., & Zaccolo, M. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12017 · Cited by 27
Thymosin α-1 does not correct F508del-CFTR in cystic fibrosis airway epithelia
Tomati, V., Caci, E., Ferrera, L., Pesce, E., Sondo, E., Cholon, D. M., Quinney, N. L., Boyles, S. E., Armirotti, A., Ravazzolo, R., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98699 · Cited by 27
Generation of Human Nasal Epithelial Cell Spheroids for Individualized Cystic Fibrosis Transmembrane Conductance Regulator Study
Brewington, J. J., Filbrandt, E. T., LaRosa, F. J., Moncivaiz, J. D., Ostmann, A. J., Strecker, L. M., & Clancy, J. P. (2018) · Journal of Visualized Experiments · doi:10.3791/57492 · Cited by 27
Early pulmonary inflammation and lung damage in children with cystic fibrosis
Schultz, A., & Stick, S. M. (2015) · Respirology · doi:10.1111/resp.12521 · Cited by 28
Pharmacological Chaperones for Enzyme Enhancement Therapy in Genetic Diseases
Aymamí, J., Barril, X., Rodríguez‐Pascau, L., & Martinell, M. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.74 · Cited by 27
Searching for Combinations of Small-Molecule Correctors to Restore F508del–Cystic Fibrosis Transmembrane Conductance Regulator Function and Processing
Boinot, C., Souchet, M. J., Ferru-Clément, R., & Becq, F. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.214890 · Cited by 29
Cyclodextrins reduce the ability of Pseudomonas aeruginosa outer-membrane vesicles to reduce CFTR Cl− secretion
Barnaby, R., Koeppen, K., & Stanton, B. A. (2018) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00316.2018 · Cited by 27
Furocoumarins as multi-target agents in the treatment of cystic fibrosis
Carbone, A., Montalbano, A., Spanò, V., Musante, I., Galietta, L. J. V., & Barraja, P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.025 · Cited by 27
Pharmacological Correctors of Mutant CFTR Mistrafficking
Pedemonte, N., & Galietta, L. J. V. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00175 · Cited by 29
Direct interaction of a CFTR potentiator and a CFTR corrector with phospholipid bilayers
Baroni, D., Zegarra‐Moran, O., Svensson, A., & Morán, Ó. (2014) · European Biophysics Journal · doi:10.1007/s00249-014-0956-y · Cited by 25
The major cystic fibrosis causing mutation exhibits defective propensity for phosphorylation
Pasyk, S., Molinski, S. V., Ahmadi, S., Ramjeesingh, M., Huan, L., Chin, S., Du, K., Yeger, H., Taylor, P. P., Moran, M. F., et al. (2014) · PROTEOMICS · doi:10.1002/pmic.201400218 · Cited by 26
An overview on chemical structures as ΔF508-CFTR correctors
Spanò, V., Montalbano, A., Carbone, A., Scudieri, P., Galietta, L. J. V., & Barraja, P. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.07.037 · Cited by 26
Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors
Amico, G., Brandas, C., Morán, Ó., & Baroni, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215463 · Cited by 27
An automated single-molecule FRET platform for high-content, multiwell plate screening of biomolecular conformations and dynamics
Hartmann, A. J., Sreenivasa, K., Schenkel, M., Chamachi, N. G., Schake, P., Krainer, G., & Schlierf, M. (2023) · Nature Communications · doi:10.1038/s41467-023-42232-3 · Cited by 26
Cystic fibrosis bone disease: is the CFTR corrector C18 an option for therapy?
Velard, F., Delion, M. F., Lemaire, F., Tabary, O., Guillaume, C., Pimpec‐Barthes, F. L., Touqui, L., Gangloff, S. C., Sermet‐Gaudelus, I., & Jacquot, J. P. (2014) · European Respiratory Journal · doi:10.1183/09031936.00174014 · Cited by 26
Personalized Medicine in Respiratory Disease
Priyadharshini, V. S., & Teran, L. M. (2015) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2015.11.008 · Cited by 27
Current insights into the role of PKA phosphorylation in CFTR channel activity and the pharmacological rescue of cystic fibrosis disease-causing mutants
Chin, S., Hung, M., & Bear, C. E. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2388-6 · Cited by 26
Long-term challenges and perspectives of pre-adolescent liver disease
Hadžić, N., Baumann, U., McKiernan, P. J., McLin, V. A., & Nobili, V. (2017) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(16)30160-1 · Cited by 26
Repairing folding-defective α-sarcoglycan mutants by CFTR correctors, a potential therapy for limb-girdle muscular dystrophy 2D
Carotti, M., Marsolier, J., Soardi, M., Bianchini, E., Gomiero, C., Fecchio, C., Henriques, S. F., Betto, R., Sacchetto, R., Richard, I., et al. (2018) · Human Molecular Genetics · doi:10.1093/hmg/ddy013 · Cited by 30
The Autophagy Inhibitor Spautin-1 Antagonizes Rescue of Mutant CFTR Through an Autophagy-Independent and USP13-Mediated Mechanism
Pesce, E., Sondo, E., Ferrera, L., Tomati, V., Caci, E., Scudieri, P., Musante, I., Renda, M., Baatallah, N., Servel, N., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01464 · Cited by 26
Current landscape of cystic fibrosis gene therapy
Plasschaert, L. W., MacDonald, K. D., & Moffit, J. S. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1476331 · Cited by 27
Carrier screening for cystic fibrosis in the new era of medications that restore CFTR function
Massie, J., Castellani, C., & Grody, W. W. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61092-2 · Cited by 31
Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation
Bulloch, M. N., Hanna, C. C., & Giovane, R. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1378094 · Cited by 24
Multimodal small-molecule screening for human prion protein binders
Reidenbach, A. G., Mesleh, M. F., Casalena, D. E., Vallabh, S. M., Dahlin, J. L., Leed, A., Chan, A. I., Usanov, D. L., Yehl, J., Lemke, C. T., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014905 · Cited by 26
Mechanism-Based Personalized Medicine for Cystic Fibrosis by Suppressing Pseudo Exon Inclusion
Shibata, S., Ajiro, M., & Hagiwara, M. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2020.08.013 · Cited by 24
Limitations and opportunities in the pharmacotherapy of ciliopathies
Phu, M. D., Bross, S., Burkhalter, M. D., & Philipp, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107841 · Cited by 24
Progress in precision medicine in cystic fibrosis: a focus on CFTR modulator therapy
Tewkesbury, D. H., Robey, R. C., & Barry, P. J. (2021) · Breathe · doi:10.1183/20734735.0112-2021 · Cited by 30
Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives
Brusa, I., Sondo, E., Falchi, F., Pedemonte, N., Roberti, M., & Cavalli, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01897 · Cited by 24
Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis
Elphick, H., & O’Reilly, R. (2013) · Drug Design Development and Therapy · doi:10.2147/dddt.s30345 · Cited by 27
Inhibiting the clathrin-mediated endocytosis pathway rescues KIR2.1 downregulation by pentamidine
Varkevisser, R., Houtman, M. J. C., Waasdorp, M., Man, J. C. K., Heukers, R., Takanari, H., Tieland, R. G., Henegouwen, P. M. P. V. B. E., Vos, M. A., & van der Heyden, M. A. G. (2012) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-012-1189-5 · Cited by 25
Post-translational dysfunctions in channelopathies of the nervous system
Terragni, B., Scalmani, P., Franceschetti, S., Cestèle, S., & Mantegazza, M. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.05.028 · Cited by 25
Positional effects of premature termination codons on the biochemical and biophysical properties of CFTR
Yeh, J., & Hwang, T. (2019) · The Journal of Physiology · doi:10.1113/jp278418 · Cited by 24
Tubular ER structures shaped by ER-phagy receptors engage in stress-induced Golgi bypass
Song, M. S., Sim, H. J., Eun, S. H., Jung, M. K., Hwang, S. J., Ham, M. H., Kwak, K., Lee, H. J., Kim, J. Y., Jang, D. G., et al. (2025) · Developmental Cell · doi:10.1016/j.devcel.2025.01.011 · Cited by 24
Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies
Jennings, M. T., & Flume, P. A. (2018) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201802-075fr · Cited by 26
Cyclic nucleotide phosphodiesterase inhibitors as therapeutic interventions for cystic fibrosis
Turner, M. J., Abbott-Banner, K., Thomas, D. Y., & Hanrahan, J. W. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107826 · Cited by 24
Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants
Borgo, C., D’Amore, C., Capurro, V., Tomati, V., Sondo, E., Cresta, F., Castellani, C., Pedemonte, N., & Salvi, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04215-3 · Cited by 28
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del)
Heneghan, M., Southern, K. W., Murphy, J. P., Sinha, I. P., & Nevitt, S. J. (2023) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010966.pub4 · Cited by 24
miR-16 rescues F508del-CFTR function in native cystic fibrosis epithelial cells
Kumar, P., Bhattacharyya, S., Peters, K. W., Glover, M. L., Sen, A., Cox, R. T., Kundu, S., Caohuy, H., Frizzell, R. A., Pollard, H. B., et al. (2015) · Gene Therapy · doi:10.1038/gt.2015.56 · Cited by 24
Self-citation
CFTR potentiators partially restore channel function to A 561 E ‐CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F 508del‐ CFTR
Wang, Y., Liu, J., Loizidou, A., Bugeja, L., Warner, R., Hawley, B. R., Cai, Z., Toye, A. M., Sheppard, D. N., & Li, H. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12791 · Cited by 25
Binding screen for cystic fibrosis transmembrane conductance regulator correctors finds new chemical matter and yields insights into cystic fibrosis therapeutic strategy
Hall, J. D., Wang, H., Byrnes, L. J., Shanker, S., Wang, K., Efremov, I. V., Chong, P. A., Forman-Kay, J. D., & AULABAUGH, A. E. (2015) · Protein Science · doi:10.1002/pro.2821 · Cited by 24
Latonduine Analogs Restore F508del–Cystic Fibrosis Transmembrane Conductance Regulator Trafficking through the Modulation of Poly-ADP Ribose Polymerase 3 and Poly-ADP Ribose Polymerase 16 Activity
Carlile, G. W., Robert, R., Matthes, E., Yang, Q., Solari, R. C. E., Hatley, R. J. D., Edge, C., Hanrahan, J. W., Andersen, R. J., Thomas, D. Y., et al. (2016) · Molecular Pharmacology · doi:10.1124/mol.115.102418 · Cited by 24
Development of Automated Patch Clamp Technique to Investigate CFTR Chloride Channel Function
Billet, A., Froux, L., Hanrahan, J. W., & Becq, F. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00195 · Cited by 24
Pharmacological analysis of CFTR variants of cystic fibrosis using stem cell-derived organoids
Chen, K. G., Zhong, P., Zheng, W., & Beekman, J. M. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.029 · Cited by 24
Treatment of human airway epithelial Calu-3 cells with a peptide-nucleic acid (PNA) targeting the microRNA miR-101-3p is associated with increased expression of the cystic fibrosis Transmembrane Conductance Regulator () gene
Fabbri, E., Tamanini, A., Jakova, T., Gasparello, J., Manicardi, A., Corradini, R., Finotti, A., Borgatti, M., Lampronti, I., Munari, S., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112876 · Cited by 24
Cyclic Peptidyl Inhibitors against CAL/CFTR Interaction for Treatment of Cystic Fibrosis
Dougherty, P. G., Wellmerling, J. H., Koley, A., Lukowski, J. K., Hummon, A. B., Cormet‐Boyaka, E., & Pei, D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01528 · Cited by 24
VO2max as an exercise tolerance endpoint in people with cystic fibrosis: Lessons from a lumacaftor/ivacaftor trial
Wilson, J. W., You, X., Ellis, M. J., Urquhart, D. S., Jha, L., Duncan, M. E., Tian, S., Harris, R. A., Kotsimbos, T. C., & Keating, D. (2020) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2020.12.006 · Cited by 24
Small-Molecule Screening for Genetic Diseases
Markossian, S., Ang, K. K. H., Wilson, C. G. M., & Arkin, M. R. (2018) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-083117-021452 · Cited by 24
Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi®) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
Favia, M., Gallo, C., Guerra, L., Venuto, D. D., Diana, A., Polizzi, A. M., Montemurro, P., Mariggiò, M. A., Leonetti, G., Manca, A., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072398 · Cited by 25

Authors: Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Stack, J. H., Straley, K. S., Decker, C. J., Miller, M., McCartney, J., Olson, E. R., Wine, J. J., Frizzell, R. A., Ashlock, M., & Negulescu, P. A.
Affiliations: Vertex Pharmaceuticals, San Diego, CA 92121;
Vertex Pharmaceuticals (United States) (US)
Stanford University (US)
Department of Cell Biology and Physiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261; and
Cystic Fibrosis Foundation (US)
Corresponding author: Negulescu, Paul A.
ORCID: Miller, Mark
Olson, Eric R.
Wine, Jeffrey J.
Venue: Proceedings of the National Academy of Sciences
Publisher: National Academy of Sciences
Published: 2011-10-05
Volume: 108
Issue: 46
Pages: 18843-18848
ISSN: 0027-8424 (ISSN-L)
1091-6490
DOI: 10.1073/pnas.1105787108
PMC: PMC3219147
OpenAlex: W2071407356
Cited by: 1,088
References: 44
Citations by year: 2026: 24 · 2025: 48 · 2024: 48 · 2023: 57 · 2022: 64 · 2021: 83 · 2020: 98 · 2019: 95 · 2018: 101 · 2017: 103 · 2016: 77 · 2015: 85 · 2014: 84 · 2013: 61 · 2012: 58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Proceedings of the National Academy of Sciences (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Funders: Cystic Fibrosis Foundation Therapeutics
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion Transport and Channel Regulation
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Inhalation and Respiratory Drug Delivery
Keywords: cystic fibrosis, F508del-CFTR, CFTR correctors, lumacaftor, endoplasmic reticulum retention, chloride secretion, bronchial epithelial cells, CFTR mutations
MeSH terms: Aminopyridines, Bronchi, Cell Line, Cells, Cultured, Chemistry, Pharmaceutical, Chlorides, Cystic Fibrosis, Drug Evaluation, Preclinical, Epithelial Cells, Homozygote, Humans, Lung, Models, Genetic, Mutation, Drug Design, Cystic Fibrosis Transmembrane Conductance Regulator, Benzodioxoles, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks